Garry Neil is the Chief Executive Officer at Avalo Therapeutics, a company focused on developing treatments for immune-mediated inflammatory diseases.
Garry Neil is the Chief Executive Officer at Avalo Therapeutics, a company focused on developing treatments for immune-mediated inflammatory diseases by targeting the IL-1β pathway. Their lead asset, abdakibart (AVTX-009), is an anti-IL-1β monoclonal antibody that recently reported positive topline data in a Phase 2 trial for hidradenitis suppurativa.
Full founder directory · Investor directory · Company funding database · Fundraising library